Applications, Efficacies, Potential Side Effects, and Expectations of CAR-T Cell Therapy in the Treatment of Acute Lymphoblastic Leukemia

Yundan Jia

doi:10.54097/yt7mkc35

Authors

Yundan Jia

DOI:

https://doi.org/10.54097/yt7mkc35

Keywords:

CAR-T therapy, cancer, acute lymphoblastic leukemia, immunotherapy, antigen.

Abstract

CAR-T cell therapy is a highly effective and powerful treatment for acute lymphoblastic leukemia (ALL), showcasing remarkable efficacy in combating this disease. Currently, several CAR-T cell therapies are available for ALL, including Kymriah and Yescarta. CAR-T is a novel targeted therapy for tumor treatment, marking a shift in modern medicine from molecular therapy to cellular therapy. ALL is a malignant blood disorder characterized by an abnormal proliferation of immature white blood cells known as lymphoblasts. These abnormal cells may be found in bone marrow, lymph nodes, spleen, and other organs. Acute lymphoblastic leukemia (ALL) predominantly affects adolescents and children, with a higher incidence observed in males. Although immunotherapy has shown promising efficacy in hematologic malignancies, the emergence of antigen escape poses a significant obstacle, limiting its use in treating solid tumors. Extensive scientific research is underway to improve the construction and manufacturing techniques of CAR-T cells and investigate novel cell configurations. This review aims to summarize the applications, efficacy, side effects, and expected outcomes of CAR-T therapy in treating ALL. It also explores strategies to enhance CAR-T therapy and provides insights into its current status and future directions in the background of ALL.

Downloads

Download data is not yet available.

References

Puckett Y, Chan O. Acute Lymphocytic Leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 27, 2022.

S. Srakocic. B-Cell Acute Lymphoblastic Leukemia: Symptoms, Treatment, and Outlook. Healthline. Published February 10, 2021. Accessed June 15, 2023. https://www.healthline.com/health/leukemia/b-cell-acute-lymphoblastic-leukemia

Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M. T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Reviews, 2018, 32(1): 36-51.

Key Statistics for Acute Lymphocytic Leukemia (ALL). www.cancer.org. Published January 12, 2023. Accessed June 15, 2023. https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/key-statistics.html

Mayo Clinic. Acute lymphocytic leukemia - Symptoms and causes. Mayo Clinic. Published 2018. Accessed June 15, 2023. https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/symptoms-causes/syc-20369077

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 2021, 22: 85–96.

How CAR T-cell Therapy Works. www.uchicagomedicine.org. Accessed June 16, 2023. https://www.uchicagomedicine.org/cancer/types-treatments/car-t-cell-therapy/how-car-t-cell-therapy-works

Burik A. Combination Therapies: Opportunities for Improved CAR-T Cell Therapy? Labiotech.eu. Published March 10, 2022. Accessed June 18, 2023. https://www.labiotech.eu/partner/combination-therapy-improved-car-t-cell-therapy/#:~:text=Combination%20therapies%20with%20CAR-T%20therapy%20are%20one%20of

Park JH, Rivière I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378(5):449-459.

Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Therapeutic Advances in Infectious Disease, 2021, 8: 204993612110367.

Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Therapeutics and Clinical Risk Management, 2020, 16: 705-714.

https://www.lls.org/treatment/types-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy. www.lls.org. Accessed June 23, 2023. https://www.lls.org/treatment/types-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy#:~:text=Another%20known%20side%20effect%20of%20CAR%20T-cell%20therapy

Bhojwani D, Bansal R, Wayne AS. Managing therapy-associated neurotoxicity in children with ALL. Hematology, 2021, 2021(1): 376-383.

Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocritical Care, 2020, 32(3): 647-666.

Miao L, Zhang Z, Ren Z, Li Y. Reactions Related to CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12: 663201.

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma. Novartis. Published June 2, 2021. Accessed June 25, 2023. https://www.novartis.com/news/media-releases/novartis-kymriah-pivotal-trial-demonstrates-strong-response-rates-and-remarkable-safety-profile-relapsed-or-refractory-follicular-lymphoma#:~:text=Kymriah%20led%20to%20responses%20for%20the%20majority%20of

Justin Benavidez. Tecartus Approved for Some Adults with B-Cell ALL - NCI. www.cancer.gov. Published November 10, 2021. Accessed June 25, 2023. https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-tecartus-adults-b-cell-all#:~:text=On%20October%201%2C%20the%20Food%20and%20Drug%20Administration

Acute Lymphoblastic Leukemia Treatment. ucsfhealth.org. Accessed June 28, 2023. https://www.ucsfhealth.org/conditions/acute-lymphoblastic-leukemia/treatment#:~:text=The%20first%20two%20phases%20use%20intensive%20chemotherapy%20medications

Elsallab M, Ellithi M, Hempel S, Abdel-Azim H, Abou-el-Enein M. Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Therapy, 2023, 30: 845–854.

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2019, 380(1): 45-56.

Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27(8): 1419-1431.

CAR T-cell Therapy and Its Side Effects. www.cancer.org. Published March 1, 2022. Accessed June 29, 2023. https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html

Castaneda-Puglianini O, Chavez JC. Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. Journal of Blood Medicine, 2021, 12: 775-783.

Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2022, 7(1): 117.

Guedan S, Alemany R. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. Frontiers in Immunology, 2018, 9: 02460.

Melanoma Skin Cancer Immunotherapy | Skin Cancer Immunotherapy. www.cancer.org. Published March 22, 2022. Accessed July 1, 2023. https://www.cancer.org/cancer/types/melanoma-skin-cancer/treating/immunotherapy.html#:~:text=Along%20with%20killing%20the%20cells%20directly%2C%20the%20viruses